Drug Trial Radar · NCT05024318
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 8, 2022
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open label, phase II, randomised, non-comparative clinical trial, evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients with localised primary clear cell renal cell carcinoma (ccRCC).
Conditions
- Renal Cell Carcinoma, Clear Cell, Somatic
Interventions
PembrolizumabDrug
Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
Stereotactic Ablative RadiotherapyRadiation
42Gy delivered in 3 fractions
NephrectomyProcedure
Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- mPR post-SABR with or without pembrolizumabTime frame: At nephrectomy performed 9-12 weeks after first dose of pembrolizumab
- CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.Time frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab
- TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variableTime frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.